Drug intelligence / Profile preview

natrunix placebo + methotrexate

Development stage: Unknown
Lead developer: XBiotech
Administration: Subcutaneous, Oral

Overview

"Natrunix placebo + methotrexate" refers to a control arm in clinical trials studying Natrunix for rheumatoid arthritis. In these trials, subjects receive a placebo injection (instead of Natrunix) along with methotrexate, a commonly used disease-modifying anti-rheumatic drug (DMARD). This combination serves as the control group to evaluate the efficacy and safety of Natrunix when added to methotrexate therapy in patients with rheumatoid arthritis who have had an inadequate response to methotrexate alone.

Targets

DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)

Beyond the preview

Go deeper on natrunix placebo + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on natrunix placebo + methotrexate.

Explore the full profile